Active substance
Oxycodone
- SFDA 10
- US FDA 53
- Health Canada 28
- US price lines 18
- NHS prices 20
- WHO EML 1
- Safety 12
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| OXYCONTIN 10 mg controlled release tablet | 10 mg | Prolonged-release tablet · Oral use | 20 Blister | SAR 207.70 | NCE · Prescription | PURDUE PHARMA LP | Valid |
| OXYCONTIN 15 mg controlled release tablet | 15 mg | Prolonged-release tablet · Oral use | 20 Blister | SAR 297.20 | NCE · Prescription | PURDUE PHARMA LP | Valid |
| OXYCONTIN 20 mg controlled release tablet | 20 mg | Prolonged-release tablet · Oral use | 20 Blister | SAR 379.70 | NCE · Prescription | PURDUE PHARMA LP | Valid |
| OXYCONTIN 30 mg controlled release tablet | 30 mg | Prolonged-release tablet · Oral use | 20 Blister | SAR 537.55 | NCE · Prescription | PURDUE PHARMA LP | Valid |
| OXYCONTIN 40 mg controlled release tablet | 40 mg | Prolonged-release tablet · Oral use | 20 Blister | SAR 673.45 | NCE · Prescription | PURDUE PHARMA LP | Valid |
| OXYCONTIN 60 mg controlled release tablet | 60 mg | Prolonged-release tablet · Oral use | 20 Blister | SAR 980.55 | NCE · Prescription | PURDUE PHARMA LP | Valid |
| OXYNORM 10MG CAPSULE | 10 mg | Capsule, hard · Oral use | 56 Blister | SAR 141.45 | NCE · Prescription | Napp pharmaceuticals limited UK | Valid |
| OXYNORM 20MG CAPSULE | 20 mg | Capsule, hard · Oral use | 56 Blister | SAR 270.55 | NCE · Prescription | Napp pharmaceuticals limited UK | Valid |
| OXYNORM 20MG/2ML AMPOULE | 10 mg/ml | Solution for injection/infusion · Intravenous, Subcutaneous | 5 Ampoule | SAR 65.70 | NCE · Prescription | Napp pharmacuticals limited UK | Valid |
| OXYNORM 5MG CAPSULE | 5 mg | Capsule, hard · Oral use | 56 Blister | SAR 70.70 | NCE · Prescription | Napp pharmaceuticals limited UK | Valid |
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS-PAIN MANAGEMENT; BURN MANAGEMENT; CHRONIC PANCREATITIS; DIABETIC NEUROPATHY; ENDOMETRIOSIS; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; LOW BACK PAIN; NEUROPATHIC PAIN; OSTEOARTHRITIS; PAIN MANAGEMENT IN CANCER PATIENTS; POST-HERPETIC NEURALGIA; POSTOPERATIVE PAIN; RENAL AND URETERIC STONES; SICKLE CELL DISEASE - PAIN MANAGEMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ROXICODONE | 15MG; 30MG; 5MG | tablet · oral | SPECGX LLC | Prescription | 31 Aug 2000 |
| OXYCODONE HYDROCHLORIDE | 15MG; 30MG; 5MG; 10MG; 20MG | tablet · oral | SPECGX LLC | Prescription | 30 Jun 2004 |
| OXYCODONE HYDROCHLORIDE | 15MG; 30MG; 5MG; 10MG; 20MG | tablet · oral | STRIDES PHARMA INTL | Prescription | 31 Jan 2007 |
| OXYCODONE HYDROCHLORIDE | 5MG; 15MG; 30MG | tablet · oral | EPIC PHARMA LLC | Prescription | 24 Aug 2009 |
| OXYCODONE HYDROCHLORIDE | 5MG; 10MG; 15MG; 20MG; 30MG | tablet · oral | AVANTHI INC | Prescription | 31 Aug 2009 |
| OXYCONTIN | 10MG; 15MG; 20MG; 30MG; 40MG; 60MG; 80MG | tablet, extended release · oral | KNOA PHARMA | Prescription | 5 Apr 2010 |
| OXYCODONE HYDROCHLORIDE | 5MG | capsule · oral | GENUS LIFESCIENCES | Prescription | 20 Oct 2010 |
| OXYCODONE HYDROCHLORIDE | 100MG/5ML; 5MG/5ML | solution · oral | GENUS LIFESCIENCES | Prescription | 20 Oct 2010 |
| OXYCODONE HYDROCHLORIDE | 5MG; 10MG; 15MG; 20MG; 30MG | tablet · oral | RHODES PHARMS | Prescription | 9 Mar 2011 |
| OXYCODONE HYDROCHLORIDE | 5MG; 15MG; 30MG | tablet · oral | ALVOGEN | Prescription | 30 Dec 2011 |
| OXYCODONE HYDROCHLORIDE | 5MG; 15MG; 30MG | tablet · oral | AUROLIFE PHARMA LLC | Prescription | 19 Nov 2012 |
| OXYCODONE HYDROCHLORIDE | 5MG/5ML | solution · oral | HIKMA PHARMS | Prescription | 15 Jul 2013 |
| OXYCODONE HYDROCHLORIDE | 5MG; 10MG; 15MG; 20MG; 30MG | tablet · oral | AMNEAL PHARMS | Prescription | 3 Jun 2014 |
| OXYCODONE HYDROCHLORIDE | 5MG/5ML | solution · oral | ANI PHARMS | Prescription | 1 Jun 2015 |
| OXYCODONE HYDROCHLORIDE | 5MG | capsule · oral | AVANTHI INC | Prescription | 17 Aug 2015 |
| OXYCODONE HYDROCHLORIDE | 5MG | capsule · oral | NOVEL LABS INC | Prescription | 24 Aug 2015 |
| OXYCODONE HYDROCHLORIDE | 5MG; 10MG; 15MG; 30MG; 20MG | tablet · oral | EPIC PHARMA LLC | Prescription | 22 Sep 2015 |
| OXYCODONE HYDROCHLORIDE | 5MG | capsule · oral | ANI PHARMS | Prescription | 31 Mar 2016 |
| OXYCODONE HYDROCHLORIDE | 5MG; 10MG; 15MG; 20MG; 30MG | tablet · oral | NUVO PHARM | Prescription | 12 Apr 2016 |
| XTAMPZA ER | 9MG; 13.5MG; 18MG; 27MG; 36MG | capsule, extended release · oral | COLLEGIUM PHARM INC | Prescription | 26 Apr 2016 |
| OXYCODONE HYDROCHLORIDE | 5MG/5ML | solution · oral | ADAPTIS | Prescription | 23 Nov 2016 |
| ROXYBOND | 5MG; 15MG; 30MG; 10MG | tablet · oral | PROTEGA PHARMS | Prescription | 20 Apr 2017 |
| OXYCODONE HYDROCHLORIDE | 5MG/5ML; 100MG/5ML | solution · oral | ABHAI LLC | Prescription | 21 Jul 2017 |
| OXYCODONE HYDROCHLORIDE | 15MG; 30MG; 5MG; 10MG; 20MG | tablet · oral | ASCENT PHARMS INC | Prescription | 7 Aug 2017 |
| OXYCODONE HYDROCHLORIDE | 100MG/5ML | solution · oral | ADAPTIS | Prescription | 6 Sep 2017 |
28 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-OXYCODONE CR | 02306530 | 40 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-OXYCODONE CR | 02366746 | 5.0 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-OXYCODONE CR | 02366754 | 10 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-OXYCODONE CR | 02366762 | 20.0 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-OXYCODONE CR | 02366789 | 80.0 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-OXYCODONE CR | 02394766 | 15 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-OXYCODONE CR | 02394774 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-OXYCODONE CR | 02394782 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| OXY.IR | 02231934 | 5 MG | TABLET · ORAL | PURDUE PHARMA |
| OXY.IR | 02240131 | 10 MG | TABLET · ORAL | PURDUE PHARMA |
| OXY.IR | 02240132 | 20 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | PURDUE PHARMA |
| OXYNEO | 02372525 | 10 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| OXYNEO | 02372533 | 15 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| OXYNEO | 02372541 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| OXYNEO | 02372568 | 40 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| OXYNEO | 02372576 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| OXYNEO | 02372584 | 80 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| OXYNEO | 02372797 | 20 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| PMS-OXYCODONE | 02319977 | 5 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-OXYCODONE | 02319985 | 10 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-OXYCODONE | 02319993 | 20 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-OXYCODONE CR | 02309882 | 10 MG | TABLET (EXTENDED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PMS-OXYCODONE CR | 02309890 | 20 MG | TABLET (EXTENDED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PMS-OXYCODONE CR | 02309904 | 40 MG | TABLET (EXTENDED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PMS-OXYCODONE CR | 02309912 | 80 MG | TABLET (EXTENDED-RELEASE) · ORAL | PHARMASCIENCE INC |
3 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | OXYCODONE HCL (IR) 10 MG TAB | $0.16278 | per EA | 23 Sep 2026 |
| US NADAC | OXYCODONE HCL (IR) 15 MG TAB | $0.19655 | per EA | 23 Sep 2026 |
| US NADAC | OXYCODONE HCL (IR) 20 MG TAB | $0.24642 | per EA | 23 Sep 2026 |
| US NADAC | OXYCODONE HCL (IR) 30 MG TAB | $0.35692 | per EA | 23 Sep 2026 |
| US NADAC | OXYCODONE HCL (IR) 5 MG CAP | $0.37462 | per EA | 23 Sep 2026 |
| US NADAC | OXYCODONE HCL (IR) 5 MG TABLET | $0.08842 | per EA | 23 Sep 2026 |
| US NADAC | OXYCODONE HCL 100 MG/5 ML CONC | $2.19009 | per ML | 23 Sep 2026 |
| US NADAC | OXYCODONE HCL 5 MG/5 ML SOLN | $0.07353 | per ML | 23 Sep 2026 |
| US NADAC | OXYCODONE HCL 5 MG/5 ML SOLN | $0.04907 | per ML | 23 Sep 2026 |
| US NADAC | OXYCONTIN ER 10 MG TABLET | $5.8746 | per EA | 23 Sep 2026 |
| US NADAC | OXYCONTIN ER 15 MG TABLET | $8.6604 | per EA | 23 Sep 2026 |
| US NADAC | OXYCONTIN ER 20 MG TABLET | $10.95464 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Oxycodone 10mg capsules | £22.86 | 56 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 10mg modified-release tablets | £25.04 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 10mg tablets | £10.29 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 10mg/1ml solution for injection ampoules | £9.71 | 5 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 10mg/ml oral solution sugar free | £46.63 | 120 ml | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 120mg modified-release tablets | £114.38 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 15mg modified-release tablets | £38.12 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 20mg capsules | £45.71 | 56 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 20mg modified-release tablets | £50.08 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 20mg tablets | £20.57 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 20mg/2ml solution for injection ampoules | £16.00 | 5 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 30mg modified-release tablets | £76.23 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 2.2. Opioid analgesics · core
Therapeutic equivalent to morphine for Pain
Safety signals and safety-related labeling changes
- US FDA 22 Dec 2025 OXAYDO — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 OXYCODONE HYDROCHLORIDE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 OXYCODONE HYDROCHLORIDE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 OXYCODONE HYDROCHLORIDE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 OXYCONTIN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 PERCODAN — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 ROXICODONE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 ROXYBOND — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2025 XTAMPZA ER — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Sep 2018 TARGINIQ — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Sep 2018 XARTEMIS XR — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 16 Dec 2016 TROXYCA ER — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Oxycodone
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.